Myocardial Infarction) compared higher-dose edoxaban regimen (HD-ER) and lower-dose edoxaban regimen with well-managed warfarin in 21 105 patients with atrial fibrillation. The risk factors and clinical impact of gastrointestinal bleeding (GIB) in this trial have not been described in detail.
T
he nonvitamin K antagonist oral anticoagulants (NOACs) offer greater safety, convenience, and effectiveness compared with vitamin K antagonists (VKAs) such as warfarin. [1] [2] [3] [4] Because of these features, NOACs are gaining acceptance as first-line agents for stroke prevention in atrial fibrillation (AF) 5 and treatment of venous thromboembolism. 6 In the pivotal trials of the NOACs, dabigatran, rivaroxaban, and higher-dose edoxaban regimen (HD-ER) were associated with increased risk of major gastrointestinal bleeding (MGIB) compared with warfarin. 1, 3, 7 In contrast, patients taking apixaban 4 and dabigatran 110 mg BID 3 did not have higher rates of GIB; the lower dose edoxaban regimen (LD-ER) was noted to be associated with fewer GIB in comparison to warfarin. A meta-analysis of these trials demonstrated significantly less intracranial bleeding with the NOACs than with warfarin (hazard ratio [HR] , 0.48; 95% confidence interval [CI] , 0.39-0.59; P<0.0001) but more MGIB (HR, 1.25; 95% CI, 1.01-1.55; P=0.03). 7 Therefore, bleeding with the NOACs seems to be organ specific.
Results from registries and analyses of claims databases support the observation that the rates of MGIB are greater with the NOACs than with VKAs, whereas the rates of intracranial bleeding are lower. 8 The explanation for the increased risk of GIB with the NOACs is uncertain. One hypothesis is that it reflects the topical anticoagulant effect of nonabsorbed drug on lesions within the gastrointestinal tract. 9 Concomitant intake of antiplatelet agents, such as aspirin, and nonsteroidal anti-inflammatory drugs further increases the risk of GIB. 10, 11 Therefore, it is important to learn more about these and other risk factors for GIB with the NOACs and the clinical outcomes of patients with these bleeds because the fear of GIB often dissuades clinicians from prescribing NOACs.
Edoxaban is an oral factor Xa inhibitor that is licensed for stroke prevention in patients with nonvalvular AF and for treatment of venous thromboembolism. The ENGAGE AF-TIMI 48 trial (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis In Myocardial Infarction) trial compared 2 once-daily regimens of edoxaban with well-managed warfarin (median time-in-therapeutic range=68.4%) in 21 105 patients with AF at moderate to high risk of stroke. 2 Higher-dose edoxaban regimen was noninferior to warfarin for prevention of stroke or systemic embolism and was associated with lower rates of overall major bleeding (including intracranial hemorrhage and death from cardiovascular cause). Because the lower-dose edoxaban regimen (LD-ER) was inferior to warfarin for prevention of ischemic stroke, only the HD-ER is approved for clinical use. 12 In this study, we report the results of an analysis of predictors, outcomes, and laboratory variables associated with first-time MGIB events that occurred during the ENGAGE AF-TIMI 48 trial.
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METHODS
Study Design and Patient Population
The design of the ENGAGE AF-TIMI 48 trial has been reported. 2, 13 This randomized, double-blind, double-dummy trial compared 2 once daily edoxaban regimens, a 60 mg HD-ER and a 30 mg LD-ER with warfarin dose-adjusted to achieve an international normalized ratio of 2.0 to 3.0. The trial was approved by an institutional review committee and subjects gave informed consent.
In both edoxaban arms, the dose was halved if patients had any one of the following: moderate renal impairment defined as creatinine clearance (CrCl) of 30 to 50 mL/ min, body weight ≤60 kg, or concurrent use of a potent P-glycoprotein inhibitor such as quinidine, verapamil, or dronedarone. Inclusion criteria included: age ≥21 years, AF documented within the past 12 months, and a CHADS 2 score of ≥2. 13, 14 Because dose reduction at randomization occurred in 25% of patients in each of the edoxaban arms, the HD-ER consisted of 75% treated with 60 mg and 25% treated with 30 mg, whereas the LD-ER consisted of 75% of patients treated with 30 mg and 25% treated with 15 mg once daily. Key exclusion criteria included: known coagulopathy, overt GIB, active peptic ulcer within the past year, CrCl <30 mL/ min, or need for dual antiplatelet therapy. The recommended dose of aspirin, if used, was ≤100 mg daily. The study enrolled VKA experienced (defined as at least 2 months of continuous anticoagulation at any time before randomization) as well as VKA naïve patients. 
WHAT IS KNOWN
WHAT THE STUDY ADDS
• In ENGAGE AF-TIMI 48, only 10% of MGIBs were life-threatening and 2% were fatal.
• The MGIB risk associated with edoxaban is increased by risk factors such as increased age, prior GIB, and concomitant aspirin use.
• Markers of severe MGIB were similar with higherdose edoxaban and warfarin, whereas the need for surgery to manage MGIB was more common with warfarin.
The principal safety end point of the ENGAGE AF-TIMI 48 trial was major bleeding as defined by the International Society on Thrombosis and Haemostasis, 15 which included fatal bleeding, bleeding into a critical organ, or bleeding that caused a decrease in transfusion-adjusted hemoglobin ≥2 g/ dL. A life-threatening (LT) bleed was defined as a major bleeding event that was either intracranial or resulted in hemodynamic compromise requiring intervention but was not fatal. 15 Bleeding events were adjudicated by an independent committee that was blinded to treatment arm.
Analysis Plan for the Current Study
The impetus for the current retrospective analysis was the observation that MGIB was the only subcategory of major bleeding that occurred at a significantly increased annual rate with HD-ER than with warfarin. The analysis plan was created by 2 of the investigators (Drs Aisenberg and Weitz) and approved by the ENGAGE AF-TIMI 48 Publications Committee. The plan called for an analysis of all first MGIB in study patients, with attention particularly to clinical outcome, severity, risk factors (including demographic and clinical characteristics), prior medical history, and concomitant medications. To assess the severity of MGIB, 5 potential markers of bleeding severity were evaluated: surgical intervention, transfusion of ≥ 4 U of packed red blood cells to manage bleeding, need for hospitalization, overt bleeding associated with ≥5 g/ dL decrease in hemoglobin, and permanent drug discontinuation. The TIMI (Thrombolysis In Myocardial Infarction) study group performed all analyses utilizing raw data gathered during the trial, independent of the sponsor of the ENGAGE AF-TIMI 48 trial.
The authors support the spirit and intent of sharing of clinical trial data. We encourage interested parties to contact the corresponding author directly for further discussions.
Measurements of Edoxaban Concentrations
Trough edoxaban concentrations were measured in blood samples collected at day 29 in 6780 patients randomized to edoxaban. Trough levels were measured because such values have previously been shown to correlate with the risks of bleeding and stroke. 16, 17 The median time from the last edoxaban dose to blood sample collection was 20 hours (interquartile range [IQR], 15.4-24.3 hours). Plasma edoxaban concentrations were quantified in a central laboratory (Quintiles Bioanalytical and ADME Laboratories, Ithaca, NY) using turbo ion spray liquid chromatography-mass spectrometry. Samples were excluded if any of the following occurred: sample handling errors, samples were taken outside of the time window, the quantification threshold of detection of 0.764 ng/mL was not reached, or if a GIB event occurred before the sample was collected.
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Statistical Analyses
Patients who received ≥1 dose of study drug (safety cohort) were included in this analysis. Only bleeding events that occurred while patients were on treatment and for up to 3 days after the last dose of study drug were included in the analysis. Baseline characteristics in patients with versus without MGIB were compared using the χ 2 test for categorical variables and the Kruskal-Wallis test for continuous variables. A multivariable model was constructed to identify independent predictors of MGIB using baseline characteristics that had P values <0.05 on univariate analysis.
To compare the relative risk of MGIB by randomized treatment group, HRs and 95% CI were calculated using an adjusted Cox proportional hazards models, adjusted for the randomization stratification factors (CHADS 2 score of 2 or 3 versus a score of 4-6 and status with respect to the need for a reduction in the edoxaban dose). We confirmed the proportionality hazards assumption for the model predicting MGIB using Schoenfeld residuals.
Aspirin was analyzed as a time-varying covariate to account for changing status of aspirin use throughout the trial. Cox proportional hazards models were adjusted also for sex, age, race, geographic region, body mass index, smoking status, alcohol use, prior stroke or transient ischemic attack, hypertension, coronary artery disease, dyslipidemia, congestive heart failure, diabetes mellitus, increased risk of falling, hepatic disease, neuropsychiatric disease, prior non-ICH bleed, use of antiplatelet agents at randomization, and CrCl at randomization.
To permit the comparison of patients treated with edoxaban with those randomized to warfarin who had a similar quality of management of anticoagulation, we calculated center-based time in therapeutic ranges (cTTR) as described previously. 2, 18 First, the average of the TTR for each individual randomized to warfarin was calculated, and the individual randomized to warfarin values at each center were then averaged to generate a single center-based TTR (cTTR) for each participating site. Analyses were then stratified by cTTR above or below the median cTTR to permit for adjustment for the quality of anticoagulant management relevant to both treatment arms. The average of the TTR for each individual randomized to warfarin was calculated, and the individual randomized to warfarin values at each center were averaged to generate a single cTTR for each participating site as described previously. 2, 18 Analyses were then stratified by cTTR above or below the median cTTR.
The estimated probability of survival after an MGIB was plotted against edoxaban concentrations. A smoothing method was then used to provide an estimate of the impact of edoxaban concentration on the survival rate at 3 years.
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A 2-sided P value <0.05 was considered statistically significant. No adjustments were made for multiple comparisons. Analyses were performed independently by the TIMI Study Group using Stata v12.1 and SAS v9.2.
RESULTS
A total of 591 first-time MGIBs occurred in 579 patients (198 in the warfarin group and 240 and 141 in the HD-ER and LD-ER groups, respectively) during the ENGAGE AF-TIMI 48 trial (overall incidence of 2.75% during 2.8 years median follow-up, the annual incidence of 1.22%). Of these MGIB, 12 patients had simultaneous upper and lower GIB, 339 patients had upper GIB (0.73% per year) and 228 (0.50% per year) had lower GIB only. A total of 63 (10.7%) patients had LT or fatal GIB (0.13% per year) of which 12 (0.03% per year) were fatal.
Baseline Clinical Characteristics Associated With MGIB
Numerous baseline clinical characteristics were associated with an increased risk of MGIB (Table 1) . In the multivariable model, the strongest independent predictors of GIB were advanced age, history of heart failure, proton pump inhibitor use, smoking, increased body mass index, and use of aspirin ( Table I in the Data Supplement). No major differences in baseline clinical characteristics among patients with MGIB were noted between the 3 treatment arms with MGIB (Table II in the Data Supplement).
Association of MGIB With Concomitant Aspirin
A total of 37.5% of patients who experienced an MGIB took aspirin at the time of randomization versus 29.0% of those who did not experience an MGIB (adjusted P<0.001). A time-variant covariate analysis confirmed the increased risk of MGIB associated with concomitant aspirin intake (HR adj , 1.31 95% CI [1.08-1.58]; P=0.006), and there was no evidence for a difference in the effect of aspirin on risk of MGIB between HD-ER and warfarin treatments (P interaction =0.55).
Rates of Major and LT/Fatal GIB by Treatment Arm
Although, as previously reported, 12 the annual incidence of MGIB was higher in patients randomized to HD-ER compared with warfarin (1.53% versus 1.25%), there was no difference in the incidence of LT or fatal GIB between these arms (0.15% per year versus 0.18% per yr, HR, 0.80 [0.46-1.38]; P=0.43; Table 2 ). Correspondingly, the incidence of MGIB events that were neither LT nor fatal (ie, the least severe MGIB events) was higher in the HD-ER group than in the warfarin group (1.41% per year versus 1.07% per year; P=0.007). The annual incidence of upper GI tract major bleeding was higher with HD-ER than with warfarin (0.82% per year versus 0.58% per year; HR, 1.40 95% CI [1.07-1.83]; P=0.013); there was a similar trend with lower GIB (0.61% per year versus 0.49% per year, HR, 1.24 95% CI [0.92-1.68]; P=0.15). In the warfarin and HD-ER groups, LT or fatal GIB was more often from the upper than the lower GI tract (ratio upper: lower of 3.8:1 and 1.9:1, respectively). Among patients treated with LD-ER, the annual incidence of MGIB (0.87% per year), LT or fatal GIB (0.07% per year), and non-LT/fatal bleeding (0.81% per year) were each significantly less frequent than among patients treated with HD-ER or warfarin ( Table 2 ). In the LD-ER cohort, the ratio of upper:lower GI tract LT or fatal bleeding was 4.5:1.
Markers of GIB Severity
The annual rate of GIB requiring surgical intervention was lower in the HD-ER group than in the warfarin group (0.04% versus 0.12% per year, respectively; HR, 0.37; 95% CI, 0.16-0.88; P=0.025; 
03).
The rates of each of the 5 more serious subgroups of MGIB were numerically lower with the LD-ER than with warfarin, with significant reductions of 33% to 49% in the rates of hospitalization, hemoglobin decrease of ≥5 g/dL, and drug discontinuation because of MGIB (Table 3) . After an MGIB, 26% of patients permanently discontinued anticoagulation therapy; rates of permanent drug discontinuation with LD-ER were lowest (0.20% per year), and higher but similar with HD-ER (0.38% per year) and warfarin (0.39% per year).
Time to First GIB by Treatment Arm
MGIB events appeared to occur at a steady rate throughout the study period in each study arm, without evidence of either an increased MGIB rate during the initial 6 months of treatment or of a plateau during the later months of treatment ( Figure 1) . A similar linear risk of MGIB over time was observed in VKA naive and experienced patients ( Figure I in the Data Supplement). Figure 2 highlights the risk of MGIB with warfarin and HD-ER in various patient subgroups. There was no evidence for effect modification by age, sex, concomitant aspirin use, dose-reduction status, or prior VKA experience. However, effect modification occurred based on baseline hemoglobin concentration, with higher rates of MGIB in patients with baseline hemoglobin <14 g/dL with HD-ER versus warfarin (P interaction =0.02). There was also effect modification related to baseline renal func- CI indicates confidence interval; HD-ER, higher dose edoxaban regimen; HR, hazard ratio; LD-ER, lower dose edoxaban regimen; LT, life-threatening; and MGIB, major gastrointestinal bleed. Since some patients had 2 simultaneous gastrointestinal bleeds, the sums of the individual subcategories may exceed the total. tion, with significantly higher rates of MGIB in patients with CrCl 50 to 80 mL/min with HD-ER versus warfarin, but similar rates of MGIB with HD-ER and warfarin in those with CrCl 30 to 50 mL/min and >80 mL/min (P interaction =0.03). As illustrated in Figure 3 , patients who met the criteria for dose reduction (most commonly because of CrCl <50 mL/min) 17 had relatively lower trough edoxaban concentrations compared with those who did not have dose reduction (eg, those with CrCl 50-80 mL/min). No significant effect modification of baseline hemoglobin <14 g/dL (P interaction =0.52) or renal function on MGIB risk (P interaction =0.07) was seen in the comparison of LD-ER versus warfarin ( Figure II in the Data Supplement).
Subgroup Analyses
Relationship of Plasma Edoxaban Concentration With Risk of MGIB
Increasing plasma trough edoxaban concentrations on day 29 were associated with a higher risk of MGIB over the course of 3 years (Figure 3 ). This increase was nonlinear and occurred over the range of plasma trough edoxaban concentrations that was observed.
The median trough concentration in patients receiving HD-ER who experienced an MGIB was 40.5 ng/mL (IQR, 20.7-63.4), which was ≈25% higher than that in patients without an MGIB (32. 
DISCUSSION
The principal findings of this study are that in the entire population, MGIB occurred at an annual rate of 1.22%, but only 10% of these were LT and only 2% were fatal (annual rates of 0.13% and 0.03%, respectively); that MGIB was more frequent with HD-ER than with warfarin but lowest with LD-ER; and that there were fewer surgical interventions with HD-ER than with warfarin Multiple patient characteristics were associated with increased MGIB risk, including male sex, prior GIB, advanced age, higher HAS-BLED and CHADS 2 scores, and aspirin use. Higher rates of bleeding in patients taking single antiplatelet therapy in addition to anticoagulant have been previously reported with edoxaban. 20 In the current study, there were no interactions between drug treatment arms and GIB risk factors, including patient age (Table II in the Data Supplement) . This is similar to what was found with rivaroxaban 23 , but different from that reported with dabigatran 29 , as there was more GIB with dabigatran than with warfarin in patients >75 years of age with the 150 mg twice daily dose. A relationship between MGIB and age has not been reported with apixaban. 21 Renal dysfunction, resulting in reduced drug clearance, is a risk factor for MGIB in patients taking either NOACs or VKAs, and the increase in risk may be even higher with NOACs if the dose is not reduced appropriately. [23] [24] [25] In ENGAGE AF-TIMI 48, as expected, declining renal function was associated with an increased rate of MGIB in both the edoxaban and warfarin arms. More specifically, MGIB rates were similar in the 2 arms in patients with normal renal function (CrCl ≥80 mL/ min) and with moderate renal dysfunction (CrCl, 30-50 mL/min), but when renal dysfunction was mild (CrCl, 50-80 mL/min), there were more GIBs with HD-ER versus warfarin. 26 This observation may be explained by the effects on concentration of protocol-mandated reductions in edoxaban dose based on kidney function. Specifically, mean trough edoxaban concentra- Baseline anemia is an established predictor of major bleeding. 27 In our study, MGIB was associated with a lower mean baseline hemoglobin concentration (Table 1) . This increased susceptibility to GIB in patients with lower baseline hemoglobin concentrations may be because of an underlying, occult abnormality of the gastrointestinal mucosa (eg, a mucosal ulcer or angioectasia). Furthermore, baseline hemoglobin <14 g/dL was associated with significantly higher rates of GIB with HD-ER compared with warfarin (P interaction , 0.02), which suggests that the anticoagulation effect of edoxaban may be more likely than that of warfarin to provoke bleeding from occult mucosal gastrointestinal abnormalities.
Although MGIB events occurred more frequently with HD-ER than with warfarin, this excess was restricted to MGIB events that were neither LT nor fatal. Thus, the rates of LT or fatal GIB events were similar with HD-ER and warfarin. Likewise, clinical markers of severe GIB, such as transfusion ≥4 U of packed red blood cell or hospitalization were no more frequent with HD-ER than with warfarin. We hypothesize that this finding reflects the shorter half-life of edoxaban relative to warfarin. Double-blinding of the study drugs and encryption of the international normalized ratio-encrypting were maintained throughout the trial in all patients. Also, the identical reversal agents (eg, prothrombin complex concentrates) were recommended for anticoagulation-associated bleeding in patients taking edoxaban and warfarin. Therefore, we doubt that the absence of a specific antidote for edoxaban influenced the relative rates of surgical intervention between the treatment arms.
The current analysis shows that the risk for GIB with warfarin and edoxaban is not front-loaded but continues over the entire treatment period. This observation contrasts with earlier, less robust data with warfarin, 28 and more recent data with dabigatran 30 and rivaroxaban, 23 which suggest a higher risk of GIB in the first 6 to 12 months after starting treatment. These different conclusions likely reflect differences in study design (eg, the exclusion of patients with a recent history of major bleeding and 50% dose reduction in ENGAGE AF-TIMI 48 in selected patients), and study populations.
Our analysis also provides information about the impact of edoxaban dose and trough edoxaban concentration (which correlates with anti-FXa activity) on the risk of GIB. As expected, the LD-ER achieved lower concentrations than HD-ER, and this correlated with lower rates of bleeding. Likewise, patients with trough edoxaban concentrations at the higher end of the observed concentration range (>125 ng/mL, a level achieved by only 4.4% of patients randomized to HD-ER) experienced an ≈4-fold greater risk of GIB than patients at the lower end of the concentration range (<25 ng/mL; Figure 3) . The probability curve for an MGIB event (N=232 in ENGAGE AF-TIMI 48) as a function of edoxaban concentration ( Figure 3 ) is similar to the curve for major bleeding into any organ (N=418). 17 Therefore, although we did not specifically test the impact of our observations about MGIB on the net clinical benefit of edoxaban versus warfarin, the current data would seem to support the conclusions of our recently-published net clinical benefit model. 30 Wide IQRs were observed along the spectrum of trough edoxaban concentration, presumably because of pharmacodynamic and other practical factors (eg, the number of hours between the patient's last drug dose and the relevant phlebotomy). This variability would render unhelpful the routine measurement of edoxaban concentration as a safety strategy.
Approximately 60% of the oral edoxaban dose is absorbed across the gastrointestinal mucosa. Therefore, it can be expected that a higher edoxaban dose will produce both a higher plasma drug level and (because of unabsorbed edoxaban) a higher drug concentration in the lumen and on the mucosal surface of the jejunum, ileum, and colon. Phase I studies indicated that, on average, 62.2% of edoxaban dose was found in stool, a result of unabsorbed drug and hepatobiliary excretion of the systematically absorbed drug. 24 Thereby, systemic and topical anti-Factor Xa activity may contribute to the dose-related increase in GIB. A dose-related increase in MGIB also has been reported with dabigatran, whereas the impact of anticoagulant dose on rivaroxaban-or apixaban-associated GIB have not been reported. 3, 31 Some limitations require comment. Despite a protocol-specified effort to obtain an accurate edoxaban concentration, the time-to-last dose was variable. Although MGIB was a secondary end point in ENGAGE AF-TIMI 48, an analysis of MGIB was not prespecified. Because MGIB events, and even more so LT or fatal GIB events, were rare, our study (despite a total N=21 105) had relatively low power to demonstrate differences in MGIB between treatment groups. Because patients were not required to maintain a daily concomitant medication log, contemporaneous association of a bleeding event to a concurrent medication (eg, a PRN nonsteroidal anti-inflammatory drug) could not be derived. We did not systematically collect granular data (eg, diagnostic endoscopy utilization) related to all MGIB events, nor did we collect data related to SSRI use, which has also been associated with GIB. We did not adjust for multiple comparisons as we consider these analyses exploratory in nature; thus, we cannot exclude the possibility that some of the findings were because of chance. Additional prospectively designed studies targeting different edoxaban concentrations would be needed to establish an optimal concentration range to balance efficacy and safety.
In conclusion, the current study demonstrates that although the annual risk of MGIB in anticoagulated patients is 1.22%, only ≈1 in 10 of these bleeds is LT and only 1 in 50 is fatal. The risk of MGIB is higher with the HD-ER than with warfarin. Although the rate of LT or fatal bleeding was low in both the warfarin and HD-ER groups, the need for surgical intervention, which is a clinical marker of severe bleeding, was lower with HD-ER than with warfarin. Modifiable risk factors (eg, antiplatelet usage) are associated with GIB in both edoxaban and warfarin.
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